Advances in Cancer Research
AEG-1/MTDH/Lyric Implicated in Multiple Human Cancers
- 1st Edition, Volume 120 - August 13, 2013
- Latest edition
- Editors: Devanand Sarkar, Paul B. Fisher
- Language: English
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are prese… Read more
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics. This volume covers AEG-1/MTDH/Lyric implicated in multiple human cancers.
- Provides information on cancer research
- Outstanding and original reviews
- Suitable for researchers and students
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.
Chapter One. AEG-1/MTDH/LYRIC, the Beginning: Initial Cloning, Structure, Expression Profile, and Regulation of Expression
- 1 Introduction
- 2 Initial Cloning
- 3 Structure of AEG-1/MTDH/LYRIC
- 4 Evolution of AEG-1/MTDH/LYRIC
- 5 Expression Profile
- 6 Regulation of Gene Expression
- 7 Concluding Remarks
- Acknowledgments
- References
Chapter Two. AEG-1/MTDH/LYRIC: Clinical Significance
- 1 Introduction
- 2 Gastrointestinal System
- 3 Genitourinary System
- 4 Nervous System
- 5 Respiratory System: Nonsmall Cell Lung Cancer
- 6 Head and Neck Cancer
- 7 Osteosarcoma
- 8 Lymphoma
- 9 Anti-AEG-1/MTDH/LYRIC Antibody as a Biomarker for Cancer
- 10 Clinical Significance of AEG-1/MTDH/LYRIC Polymorphism
- 11 Conclusion
- Acknowledgments
- References
Chapter Three. AEG-1/MTDH/LYRIC: Signaling Pathways, Downstream Genes, Interacting Proteins, and Regulation of Tumor Angiogenesis
- 1 Introduction
- 2 Cloning of AEG-1/MTDH/LYRIC
- 3 AEG-1/MTDH/LYRIC: High Expression Is Linked to Cancer Aggressiveness
- 4 AEG-1/MTDH/LYRIC: Signaling Pathways
- 5 AEG-1/MTDH/LYRIC: Downstream Molecules and Interacting Proteins
- 6 AEG-1/MTDH/LYRIC and Angiogenesis
- 7 Conclusion and Future Perspectives
- Acknowledgments
- References
Chapter Four. Pleiotropic Roles of AEG-1/MTDH/LYRIC in Breast Cancer
- 1 Introduction
- 2 Aberrations of AEG-1/MTDH/LYRIC in Breast Cancer
- 3 Variants of AEG-1/MTDH/LYRIC in Breast Cancer
- 4 Regulation of AEG-1/MTDH/LYRIC in Breast Cancer
- 5 AEG-1/MTDH/LYRIC in Breast Cancer Growth Control
- 6 AEG-1/MTDH/LYRIC and EMT in Breast Cancer
- 7 AEG-1/MTDH/LYRIC and Breast Cancer Metastasis
- 8 AEG-1/MTDH/LYRIC and Chemoresistance
- 9 Molecular Understanding of AEG-1/MTDH/LYRIC
- 10 Therapeutic Targeting of AEG-1/MTDH/LYRIC
- 11 Concluding Remarks and Future Perspectives
- References
Chapter Five. Drug Resistance Mediated by AEG-1/MTDH/LYRIC
- 1 Introduction: AEG-1/MTDH/LYRIC, a Gene Involved in Cancer Metastasis and Drug Resistance
- 2 Mechanisms of AEG-1/MTDH/LYRIC-Mediated Drug Resistance
- 3 AEG-1/MTDH/LYRIC Downstream Genes Identified by Microarray
- 4 Potential Contribution of Genes Located Near AEG-1/MTDH/LYRIC on Chromosome 8q22 Locus to Cancer Drug Resistance
- 5 Conclusions and Future Perspectives
- Acknowledgments
- References
Chapter Six. The Role of AEG-1/MTDH/LYRIC in the Pathogenesis of Central Nervous System Disease
- 1 Introduction
- 2 The Role of AEG-1/MTDH/LYRIC in CNS Disease Pathogenesis
- 3 Structure and Localization of Astrocyte-Elevated Gene-1 in the CNS
- 4 The Role of AEG-1/MTDH/LYRIC in Brain Tumor Pathogenesis
- 5 Conclusions
- References
Chapter Seven. AEG-1/MTDH/LYRIC in Liver Cancer
- 1 Hepatocellular Carcinoma: Etiology, Epidemiology, and Pathogenesis
- 2 HCC: The Molecular Abnormalities
- 3 AEG-1/MTDH/LYRIC is Overexpressed in HCC
- 4 Biological Consequence of AEG-1/MTDH/LYRIC Overexpression in HCC
- 5 AEG-1/MTDH/LYRIC Downstream Genes
- 6 AEG-1/MTDH/LYRIC-Interacting Proteins
- 7 The Role of AEG-1/MTDH/LYRIC in Hepatocarcinogenesis: Novel Insights from a Mouse Model
- 8 Conclusion
- References
- Edition: 1
- Latest edition
- Volume: 120
- Published: August 13, 2013
- Language: English
DS
Devanand Sarkar
Dr. Sarkar received his MBBS from Dhaka Medical College, Bangladesh and PhD from Nagoya University, Japan. After postdoctoral training in Columbia University, NY he joined Virginia Commonwealth University (VCU) as a faculty where he is now a Professor in the Department of Human and Molecular Genetics, and Associate Director of Education and Training at Massey Cancer Center. Dr. Sarkar’s research focuses on identifying novel regulators of hepatocellular carcinoma (HCC), especially obesity-induced HCC, and developing targeted gene- and immunotherapy based on the accrued knowledge. Dr. Sarkar has published more than 280 papers and his research is funded by NCI, NIDDK and DOD.
Affiliations and expertise
Professor in the Department of Human and Molecular Genetics, and Associate Director of Education and Training at Massey Cancer Center, Virginia Commonwealth University (VCU)PF
Paul B. Fisher
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Affiliations and expertise
Department of Cellular, Molecular and Genetic Medicine, VCU Institute of Molecular Medicine, VCU Massey Comprehensive Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, United StatesRead Advances in Cancer Research on ScienceDirect